RiyadhA biosimilar of macular degeneration drug Lucentis has entered trials in Saudi Arabia and Jordan, the first Middle East sites in the FORCE study.
The original trial excluded the region; FYB-201 costs less than Lucentis.
Outcomes benchmarked against European data will determine whether Gulf health systems expand biosimilar access.
Sources: Nature
WHAT AMD ACTUALLY IS
Age-related macular degeneration destroys the macula — the central few millimeters of the retina responsible for sharp, straight-ahead vision. Peripheral vision survives, but reading, faces, and screens disappear. It is the leading cause of blindness in adults over 60 in high-income countries.
THE VEGF MECHANISM
Vascular endothelial growth factor (VEGF) is the signal that tells the body to grow new blood vessels. In wet AMD it misfires, sprouting fragile vessels that leak fluid and blood into the retina. Ranibizumab is an antibody fragment that binds VEGF and neutralizes it. The injection goes directly into the eyeball, monthly, often for life.
WHAT A BIOSIMILAR IS
Small-molecule drugs (aspirin, statins) can be copied atom-for-atom — those copies are generics. Biologics like ranibizumab are produced in living cells and are too complex to replicate exactly. A biosimilar is a close-enough copy that has to prove equivalent clinical effect through its own trials. This is why biosimilars cost more to develop than generics but still come in at 30–70% below the originator.
WHY TRIALS EXCLUDED THE GULF
Pivotal drug trials cluster in North America and Europe because regulators there set the global standard and trial infrastructure is mature. The cost of extending a Phase 3 to new geographies is high and the marginal regulatory benefit is low — manufacturers reach FDA and EMA approval without Gulf sites, then market the drug globally on those credentials. The downside: efficacy data for Middle Eastern and South Asian populations often arrives years late, if at all.
THE COST GEOMETRY
Lucentis launched at roughly $2,000 per injection in the US — for a drug administered monthly, often for years. Gulf health systems that cover citizens fully feel the full weight of that price; biosimilars like FYB-201 reset the math by 30–50%. The trial is not just clinical — it is fiscal due diligence before formulary inclusion.
THE OFF-LABEL SHADOW
Bevacizumab (Avastin) is a cancer drug from the same maker as Lucentis that also blocks VEGF. Ophthalmologists discovered it works for wet AMD at roughly 1/40th the cost when split into eye-sized doses. The CATT trial (2011) showed equivalent visual outcomes. Most public health systems quietly rely on bevacizumab; the biosimilar question is essentially whether the licensed-and-cheaper path can compete with the unlicensed-and-much-cheaper one.
WHY GULF DATA MATTERS
Drug response varies with genetics, comorbidities, and disease presentation. Gulf populations carry higher rates of diabetes — and diabetic macular edema responds to the same anti-VEGF drugs as AMD. Trial data anchored in the region informs not just AMD policy but the much larger diabetic retinopathy treatment question across the GCC.